PAVmed and Lucid Diagnostics Chairman & CEO Lishan Aklog, MD Named Top 50 Healthcare Technology CEO

NEW YORK – (BUSINESS WIRE) –PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (“PAVmed”), a diversified commercial-stage medical technology company, and its majority-owned subsidiary Lucid Diagnostics Inc. (Nasdaq: LUCD) (“Lucid”), a commercial-stage cancer prevention medical diagnostics company, announced today that PAVmed and Lucid The Healthcare Technology Report.

“I would like to thank The Healthcare Technology Report for this honor, ”said Dr. Aklog. “I am so fortunate to work with a rapidly growing team of the best and brightest in the industry, who can share the passion of serving patients through technology and drive long-term shareholder value through strategic execution.”

The Healthcare Technology Report described this Ky awardees as “some of the most cultivated, intelligent executives in the healthcare and technology industry.” Their “leadership and innovation remain crucial in the development of the global medical devices, cutting-edge drugs and therapeutics, and advanced diagnostics, among other technologies” all while making “momentous contributions and improvements across the globe.”

The editors carefully evaluated hundreds of CEOs across the fields of healthcare, medical devices, biotech, healthcare software, and more. The list includes CEOs from industry leaders such as Medtronic, Edwards Lifesciences and ResMed. Like Dr. Aklog, many of the recipients are founders or co-founders of their organizations.

About Lishan Aklog, MD

Dr. Lishan Aklog is Chairman & CEO of PAVmed Inc. (Nasdaq: PAVM), a diversified, commercial-stage medical technology company which is co-founded, and its majority-owned subsidiary Lucid Diagnostics Inc., and cancer prevention medical diagnostics company (Nasdaq: LUCD). He also serves on the board of the leading medtech industry group, AdvaMed, and as the independent public company director. Previously co-founded and owned®. Dr. Aklog has been developed for leading medtech companies and is the inventor of dozens of patents. The Healthcare Technology Report Previously recognized as a Top Healthcare Technology CEO of 2021. Prior to entering the life sciences industry as an entrepreneur and executive, Dr. Aklog had a distinguished career as an innovator in cardiac surgery, serving on the faculty of leading academic medical centers including Harvard Medical School and Mount Sinai Medical Center, and in professional society leadership positions. He was recognized as America’s Top Doctor for over a decade. He received his undergraduate degree in Physics, magna cum laudeand MD, cum laude, from Harvard University. He completed his training at Harvard teaching hospitals and leading medical centers in London and Paris.

About PAVmed and Lucid

PAVmed Inc. is a diversified commercial-stage medical technology operating company in the medical device, diagnostics, and digital health sectors. Its major subsidiary, Lucid Diagnostics Inc., markets the EsoGuard® Esophageal DNA Test and EsoCheck® Esophageal Cell Collection Device — the first and only commercial tools for early detection of esophageal cancer. Another major subsidiary, Veris Health Inc., is developing the first intelligent implantable vascular access port with biologic sensors and wireless communication to improve personalized cancer care through remote patient monitoring. PAVmed’s CarpX® Minimally Invasive Device for Carpal Tunnel Syndrome is a limited commercial commercial release. The product pipeline also includes the EsoCure ™ Esophageal Ablation Device with Caldus ™ Technology, which complements EsoGuard and EsoCheck, the NextFlo ™ Intravenous Infusion Set, the PortIO ™ Implantable Intraosseous Vascular Access Device, and other earlier stage technologies. For more information on PAVmed, please visit www.pavmed.com, follow PAVmed on Twitter, connect with it on LinkedIn, and watch its videos on YouTube. For more information on Lucid, please visit www.luciddx.com, follow Lucid on Twitter, and connect with it on LinkedIn. For detailed information on EsoGuard, please visit www.EsoGuard.com and follow EsoGuard on TwitterFacebook and Instagram.

Forward-Looking Statements

This press release includes forward-looking statements that involve risk and uncertainties. Forward-looking statements are no statements that are not historical facts. Such forward-looking statements, which are based on the current beliefs and expectations of PAVmed’s management, are subject to risks and uncertainties, which could cause actual results to differ from the forward-looking statements. Risks and uncertainties that can cause such differences include, among other things, volatility in the price of PAVmed’s common stock; PAVmed’s Series W and Series Z warrants; general economic and market conditions; the uncertainties inherent in research and development, including the cost and time required to advance PAVmed’s products to regulatory submission; whether regulatory authorities will be satisfied with the design of PAVmed’s clinical and preclinical studies; PAVmed’s products are cleared by regulatory authorities; market acceptance of PAVmed’s and products once cleared and commercialized; PAVmed’s ability to raise additional funding as needed; and other competitive developments. In addition, PAVmed has been monitoring the COVID-19 pandemic and the pandemic’s impact on PAVmed’s businesses. PAVmed expects the significance of the COVID-19 pandemic, including the extent of its effect on its financial and operational results, . These factors are difficult or impossible to predict accurately and many are beyond PAVmed’s control. In addition, new risks and uncertainties may arise from time to time and are difficult to predict. PAVmed’s future operations, see Part I, Item IA, “Risk Factors,” in PAVmed’s most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, as may be updated in Part II, Item 1A, “Risk Factors” in any Quarterly Report on Form 10-Q filed by PAVmed after its most recent Annual Report filed with the Securities and Exchange Commission. PAVmed discovers any intention or obligation to declare any changes in its expectations or events, from those contained in the forward-looking statements.

Leave a Reply

Your email address will not be published. Required fields are marked *

Back to top button

Adblock Detected

Please consider supporting us by disabling your ad blocker